A phase 1b/2 study of cabozantinib in combination with pembrolizumab in advanced cutaneous melanoma.
- DOI
- 10.1002/cncr.70326
- Published
- 2026 Feb 15
- Container
- Cancer
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1002/cncr.70326,
title = {A phase 1b/2 study of cabozantinib in combination with pembrolizumab in advanced cutaneous melanoma.},
author = {Zakharia Y and Kim D and Freesmeier M and Frees M and Mott S and Monga V and Laux D and Javed A and Rieth J and Smestad J and Milhem M},
year = {2026},
journal = {Cancer},
doi = {10.1002/cncr.70326},
url = {https://doi.org/10.1002/cncr.70326}
}RIS
TY - JOUR TI - A phase 1b/2 study of cabozantinib in combination with pembrolizumab in advanced cutaneous melanoma. AU - Zakharia Y AU - Kim D AU - Freesmeier M AU - Frees M AU - Mott S AU - Monga V AU - Laux D AU - Javed A AU - Rieth J AU - Smestad J AU - Milhem M PY - 2026 JO - Cancer DO - 10.1002/cncr.70326 UR - https://doi.org/10.1002/cncr.70326 ER -
APA
Y, Z., D, K., M, F., M, F., S, M., V, M., D, L., A, J., J, R., J, S., & M, M. (2026). A phase 1b/2 study of cabozantinib in combination with pembrolizumab in advanced cutaneous melanoma.. Cancer. https://doi.org/10.1002/cncr.70326
Source records
- pubmed · retrieved 2026-09-24T22:49:54.062Z
- europe-pmc · retrieved 2026-09-24T22:49:54.053Z